Linezolid: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz (New article generated using Special:MetadataForm) |
mNo edit summary |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Linezolid''' is the first commercially available [[antibiotic]] of the [[oxazolidinone]] class, approved for complex vancomycin-resistant ''[[Enterococcus faecium]]'' infections, methicillin-resistant ''[[Staphylococcus aureus]]'', and complex ''[[Streptococcus pyogenes]]'' and ''S. agalactiae'' infections. It is approved for complex skin and soft tissue infections, and for [[pneumonia]]s. | |||
It has little activity against [[Gram stain|Gram-negative]] organisms. The drug can be given intravenously or orally.[[Category:Suggestion Bot Tag]] | |||
Latest revision as of 06:01, 12 September 2024
Linezolid is the first commercially available antibiotic of the oxazolidinone class, approved for complex vancomycin-resistant Enterococcus faecium infections, methicillin-resistant Staphylococcus aureus, and complex Streptococcus pyogenes and S. agalactiae infections. It is approved for complex skin and soft tissue infections, and for pneumonias.
It has little activity against Gram-negative organisms. The drug can be given intravenously or orally.